Organon & Co (OGN) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Total Revenue Chart for Organon & Co
Organon & Co (OGN) revenue for FY2025 was USD 6.2B, a -2.9% change from FY2024. Organon & Co's revenue grew from USD 10.5B in 2017 to USD 6.2B in 2025 (-40.8% over 8 years). Earnings per share grew from USD 7.11 in 2017 to USD 0.72 in 2025 (-89.9%). Revenue compound annual growth rate: 5-year CAGR of -1.0%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $3.61B
- Implied Share Price
- $13.75
- Enterprise Value
- $11.01B
- Revenue (TTM)
- $6.13B
- EBITDA
- $1.56B
- Profit Margin
- 3.41%
- Trailing P/E
- 17.63
- Forward P/E
- 5.09
- Price/Book (MRQ)
- 3.57
- Price/Sales (TTM)
- 0.59
- EV/EBITDA
- 8.39
- EV/Revenue
- 1.80
- Dividend Yield
- 0.58%
- Book Value
- $3.83
- Free Cash Flow (FY2025)
- $538.00M
- Free Cash Flow Yield
- 14.90%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.